Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential
Mariam Alamgir,1 Aalam Sohal,1,2 Kris V Kowdley1,3 1Department of Hepatology, Liver Institute Northwest, Seattle, WA, USA; 2Department of Gastroenterology and Hepatology, Creighton University, Phoenix, AZ, USA; 3Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USACorresp...
Furkejuvvon:
| Váldodahkkit: | , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Dove Medical Press
2026-03-01
|
| Ráidu: | Drug Design, Development and Therapy |
| Fáttát: | |
| Liŋkkat: | https://www.dovepress.com/efimosfermin-for-the-treatment-of-metabolic-dysfunction-associated-ste-peer-reviewed-fulltext-article-DDDT |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|